Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / I•••••• U•• H•••••••• L••

C••••• C••••••• H••••• Acquires I•••••• U•• H•••••••• L••

Add-on acquisitionclosedadd-onannounced Oct 24, 2023closed Oct 24, 2023Fact
What happened
Target
I•••••• U•• H•••••••• L••
Platform
C••••• C••••••• H•••••add-on basis: Founded in 2022, C••••• C••••••• H••••• is sponsored by H•••••• Capital Management, B••••• P••••••• S•••••••• C••••••, and The Emerson Group—and currently markets the OTC acid reducer brand, Zegerid OTC ®.
Control
Control
Share acquired
unknown
Industry
consumer / brand, consumer
Target location
CT, US
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
8 named
Buy side
  • B••••• P••••••• S•••••••• C••••••Co-investorconfirmed
    “Founded in 2022, C••••• C••••••• H••••• is sponsored by H•••••• Capital Management, B••••• P••••••• S•••••••• C••••••, and The Emerson Group—and currently markets the OTC acid reducer brand, Zegerid OTC ®.”
  • C••••• C••••••• H•••••Platformconfirmed
    “Founded in 2022, C••••• C••••••• H••••• is sponsored by H•••••• Capital Management, B••••• P••••••• S•••••••• C••••••, and The Emerson Group—and currently markets the OTC acid reducer brand, Zegerid OTC ®.”
  • H•••••• C•••••• M••••••••• L••Sponsorconfirmed
    “Founded in 2022, C••••• C••••••• H••••• is sponsored by H•••••• Capital Management, B••••• P••••••• S•••••••• C••••••, and The Emerson Group—and currently markets the OTC acid reducer brand, Zegerid OTC ®.”
Advisory side
  • S••••• A••••• L••Legal adviserconfirmed
    “S••••• A••••• L•• served as legal advisor to C••••• and Wilson Sonsini Goodrich Rosati acted as legal advisor to I••••••.”
  • S•••••Sell-side adviserconfirmed
    “S••••• acted as exclusive financial advisor to I••••••.”
Side not stated
  • J•••• B••••••••Managementconfirmed
    ““C•••••, and its impressive healthcare partners, will help I•••••• achieve its business goals more quickly and allow us to more rapidly commercialize our innovation pipeline,” said J•••• B••••••••, President and CEO of I••••••.”
  • S•••• C••••••Managementconfirmed
    ““We are very excited to be associated with these two great brands,” said S•••• C••••••, President and Chief Executive Officer of C•••••.”
  • I•••••• U•• H•••••••• L••Targetconfirmed
    “C••••• C••••••• H••••• (“C•••••”), a preeminent consumer health business that specializes in acquiring leading over the counter (“OTC”) brands, today announced that it has acquired I•••••• U•• H•••••••• L•• (“I••••••”), the parent company of I•••••• H•••••care Inc.”
Evidence
“C••••• C••••••• H••••• (“C•••••”), a preeminent consumer health business that specializes in acquiring leading over the counter (“OTC”) brands, today announced that it has acquired I•••••• U•• H•••••••• L•• (“I••••••”), the parent company of I•••••• H•••••care Inc.”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 16, 2026
C••••• C••••••• H••••• Acquires I•••••• U•• H•••••••• L•• | Private Equity Intelligence | DFX